Next Article in Journal
Development of a Deep Learning Algorithm for Periapical Disease Detection in Dental Radiographs
Next Article in Special Issue
Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer—The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol
Previous Article in Journal
Metabolic Endotoxemia, Feeding Studies and the Use of the Limulus Amebocyte (LAL) Assay; Is It Fit for Purpose?
Open AccessArticle

Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece

1
Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA
2
Roche Diagnostics (Hellas) S.A., 151 25 Marousi, Greece
3
Roche Sequencing Solutions, Pleasanton, CA 94588, USA
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(6), 429; https://doi.org/10.3390/diagnostics10060429
Received: 4 June 2020 / Revised: 18 June 2020 / Accepted: 21 June 2020 / Published: 24 June 2020
(This article belongs to the Special Issue Lung Cancer Molecular Pathology)
Within the European Union, Greece has the highest incidence of lung cancer among people under 45 years of age. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are indicated for the treatment of patients with EGFR mutation-positive metastatic non-small cell lung cancer (mNSCLC). Tumor tissue biopsy is the standard method for EGFR mutation detection but is invasive, is resource-intensive, and has risks of complications. The objective of this analysis was to estimate the financial impact on the Greek National Health System of adopting plasma biopsy and to identify the cost-optimal approach for EGFR mutation testing of patients with mNSCLC. We developed a budget impact model to estimate total costs for three EGFR mutation testing approaches: (1) plasma test, (2) combined testing (tissue and plasma test), and (3) reflex testing, compared to the current scenario of tissue biopsy only. One-way sensitivity and scenario analyses were conducted to evaluate the impact of uncertainty and variance of different input parameters on the results. In the first-line (1L) setting, base-case results showed that adopting plasma testing in a combined testing approach identified more EGFR mutation-positive patients and yielded cost savings (−€17 per correctly classified patient) relative to tissue testing alone. The reflex testing approach was the cost-optimal strategy in the second-line (2L) setting as it identified the most EGFR mutation-positive patients with cost savings of −€42 per correctly classified patient relative to tissue testing alone. This analysis suggests that access to both EGFR mutation tissue and plasma testing are important for optimizing mNSCLC treatment decisions in Greece. Inclusion of plasma testing in either a combined or reflex testing approach may be cost optimal for EGFR mutation plasma test implementation. View Full-Text
Keywords: budget impact; cost; epidermal growth factor receptor (EGFR); plasma biopsy; non-small cell lung cancer (NSCLC); companion diagnostic budget impact; cost; epidermal growth factor receptor (EGFR); plasma biopsy; non-small cell lung cancer (NSCLC); companion diagnostic
Show Figures

Figure 1

MDPI and ACS Style

Cheng, M.; Akalestos, A.; Scudder, S. Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece. Diagnostics 2020, 10, 429.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop